Biotricity Statistics
Total Valuation
Biotricity has a market cap or net worth of 1.81 million. The enterprise value is 32.61 million.
| Market Cap | 1.81M |
| Enterprise Value | 32.61M |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Biotricity has 20.07 million shares outstanding. The number of shares has increased by 7.96% in one year.
| Current Share Class | 19.91M |
| Shares Outstanding | 20.07M |
| Shares Change (YoY) | +7.96% |
| Shares Change (QoQ) | -19.15% |
| Owned by Insiders (%) | 10.09% |
| Owned by Institutions (%) | 0.24% |
| Float | 17.69M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.11 |
| PB Ratio | -0.06 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 11.18 |
| P/OCF Ratio | 11.18 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.94, with an EV/FCF ratio of 201.74.
| EV / Earnings | n/a |
| EV / Sales | 1.99 |
| EV / EBITDA | 14.94 |
| EV / EBIT | 20.81 |
| EV / FCF | 201.74 |
Financial Position
The company has a current ratio of 0.15
| Current Ratio | 0.15 |
| Quick Ratio | 0.11 |
| Debt / Equity | n/a |
| Debt / EBITDA | 12.34 |
| Debt / FCF | 166.58 |
| Interest Coverage | 0.38 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 16.24% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -5.00% |
| Weighted Average Cost of Capital (WACC) | 12.09% |
| Revenue Per Employee | 356,548 |
| Profits Per Employee | -74,880 |
| Employee Count | 46 |
| Asset Turnover | 2.72 |
| Inventory Turnover | 1.89 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -87.32% in the last 52 weeks. The beta is 1.17, so Biotricity's price volatility has been higher than the market average.
| Beta (5Y) | 1.17 |
| 52-Week Price Change | -87.32% |
| 50-Day Moving Average | 0.11 |
| 200-Day Moving Average | 0.23 |
| Relative Strength Index (RSI) | 38.05 |
| Average Volume (20 Days) | 12,783 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 5.28 |
Income Statement
In the last 12 months, Biotricity had revenue of 16.40 million and -3.44 million in losses. Loss per share was -0.13.
| Revenue | 16.40M |
| Gross Profit | 13.36M |
| Operating Income | 1.57M |
| Pretax Income | -2.69M |
| Net Income | -3.44M |
| EBITDA | 1.57M |
| EBIT | 1.57M |
| Loss Per Share | -0.13 |
Balance Sheet
The company has 1.77 million in cash and 26.93 million in debt, with a net cash position of -25.16 million or -1.25 per share.
| Cash & Cash Equivalents | 1.77M |
| Total Debt | 26.93M |
| Net Cash | -25.16M |
| Net Cash Per Share | -1.25 |
| Equity (Book Value) | -32.19M |
| Book Value Per Share | -1.87 |
| Working Capital | -31.75M |
Cash Flow
| Operating Cash Flow | 161,661 |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 5,953 |
| Net Borrowing | 155,211 |
| Free Cash Flow | 161,661 |
| FCF Per Share | 0.01 |
Margins
Gross margin is 81.47%, with operating and profit margins of 9.56% and -16.41%.
| Gross Margin | 81.47% |
| Operating Margin | 9.56% |
| Pretax Margin | -16.41% |
| Profit Margin | -16.41% |
| EBITDA Margin | 9.59% |
| EBIT Margin | 9.56% |
| FCF Margin | 0.99% |
Dividends & Yields
Biotricity does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.96% |
| Shareholder Yield | -7.96% |
| Earnings Yield | -190.65% |
| FCF Yield | 8.95% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 3, 2023. It was a reverse split with a ratio of 0.1666667.
| Last Split Date | Jul 3, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.1666667 |
Scores
Biotricity has an Altman Z-Score of -35.97 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -35.97 |
| Piotroski F-Score | 6 |